Evidence map›Paper›PMID 40026895›Full record

ArticleBiomedical engineering letters2025

Abuse-deterrent wearable device with potential for extended delivery of opioid drugs.

Myoung Ju Kim, Jae Min Park, Jun Su Lee, Ji Yang Lee, Juhui Lee, Chang Hee Min, Min Ji Kim, Jae Hoon Han, Eun Jung Kwon, Young Bin Choy

Abstract read
In one paragraph

Article in Biomedical engineering letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Interpol review of forensic drug chemistry, 2022-2025.Forensic science international. Synergy · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Myoung Ju Kim *Interdisciplinary Program in Bioengineering, College of Engineering, Seoul National University, Seoul, 08826 Republic of Korea.ORCID 0009-0005-5457-5824
Jae Min Park *Department of Medicine, Seoul National University College of Medicine, Seoul, 03080 Republic of Korea.ORCID 0009-0003-3393-5822
Jun Su Lee *Department of Medicine, Seoul National University College of Medicine, Seoul, 03080 Republic of Korea.ORCID 0009-0001-2814-4693
Ji Yang Lee *Department of Medicine, Seoul National University College of Medicine, Seoul, 03080 Republic of Korea.ORCID 0009-0001-6546-2551
Juhui Lee *Interdisciplinary Program in Bioengineering, College of Engineering, Seoul National University, Seoul, 08826 Republic of Korea.
Chang Hee MinInterdisciplinary Program in Bioengineering, College of Engineering, Seoul National University, Seoul, 08826 Republic of Korea.
Min Ji KimInterdisciplinary Program in Bioengineering, College of Engineering, Seoul National University, Seoul, 08826 Republic of Korea.
Jae Hoon HanInterdisciplinary Program in Bioengineering, College of Engineering, Seoul National University, Seoul, 08826 Republic of Korea.
Eun Jung KwonInterdisciplinary Program in Bioengineering, College of Engineering, Seoul National University, Seoul, 08826 Republic of Korea.
Young Bin ChoyInterdisciplinary Program in Bioengineering, College of Engineering, Seoul National University, Seoul, 08826 Republic of Korea.ORCID 0000-0001-6300-9377

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Unethical attempts to misuse and overdose opioids have led to strict prescription limits, necessitating frequent hospital visits and prescriptions for long-term severe pain management. Therefore, this study aimed to develop a prototype wearable device that facilitates the extended delivery of opioid drugs while incorporating abuse-deterrent functionality, referred to as the abuse deterrent device (ADD). Methods: The ADD was designed and fabricated using 3D-printed components, including reservoirs for the drug and contaminant, as well as an actuator. In vitro tests were conducted using a skin-mimicking layer and phosphate-buffered saline (PBS) to evaluate the drug release profile and the effectiveness of the ADD abuse-deterrent mechanism. Results: Under simulated skin attachment, ADD demonstrated sustained drug release with the potential to persist for up to 200 days. Upon detachment from the skin mimic, the mechanical components of the ADD facilitated immediate exposure of the contaminant to the drug and effectively halted further drug exposure throughout-diffusion. Conclusion: Wearable ADD provides a secure and practical solution for the long-term treatment of high-risk medications such as opioids, enhances patient convenience, and addresses important public health concerns. Supplementary Information: The online version contains supplementary material available at 10.1007/s13534-025-00459-7.

Indexed as

Abuse-deterrentOpioid drugsSustained drug deliveryWearable device

Identifiers

PMID40026895
PMCPMC11871182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.